Drugs / 64Cu-DOTA B-Fab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02708511 | Aug 2016 → Oct 2017 | breast carcinoma, ovarian carcinoma | Sanjiv Sam Gambhir | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 64Cu-DOTA B-Fab | “64Cu-DOTA-B-Fab as A PET Tracer for Evaluating CA6 Expression in Tumors: A First in Human Study” NCT02708511 ↗1“64Cu-DOTA B-Fab (copper Cu 64-DOTA-B-Fab).” NCT02708511 ↗ |
| Known as | Copper Cu 64-DOTA B-Fab | “Patients receive copper Cu 64-DOTA-B-Fab intravenously (IV) followed by PET/CT 60 minutes post-injection and 24 hours post-injection” NCT02708511 ↗ |
| Modality | Diagnostic / imaging agent | “64Cu-DOTA-B-Fab as A PET Tracer” NCT02708511 ↗ |
| Route | Intravenous | “copper Cu 64-DOTA-B-Fab intravenously (IV)” NCT02708511 ↗ |